{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:58:27Z","timestamp":1790715507435,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.heliyon.2024.e26658","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T11:57:19Z","timestamp":1708171039000},"page":"e26658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive factors and treatment challenges in malignant progression of relapsing-remitting multiple sclerosis"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9632-8558","authenticated-orcid":false,"given":"Masoud","family":"Ghiasian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashed","family":"Bawand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulmaz","family":"Jabarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e26658_bib1","series-title":"Bradley's Neurology in Clinical Practice","author":"Newman","year":"2021"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e26658_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158978","article-title":"Long term clinical prognostic factors in relapsing-remitting multiple sclerosis: insights from a 10-year observational study","volume":"11","author":"Bsteh","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e26658_bib3","series-title":"Adams and Victor's Principles of Neurology","author":"Allan","year":"2019"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26658_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.20197","article-title":"Clinical implications of benign multiple sclerosis: a 20\u2010year population\u2010based follow\u2010up study","volume":"56","author":"Pittock","year":"2004","journal-title":"Ann. Neurol.: Official Journal of the American Neurological Association and the Child Neurology Society"},{"key":"10.1016\/j.heliyon.2024.e26658_bib5","series-title":"EDSS Calculator: for Assessment the Disability of Patients with Multiple Sclerosis","year":"2023"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e26658_bib6","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1007\/s00415-021-10501-0","article-title":"Long-term analysis of patients with benign multiple sclerosis: new insights about the disability course","volume":"268","author":"Mathey","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.heliyon.2024.e26658_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577650","article-title":"Different neuroinflammatory gene expression profiles in highly active and benign multiple sclerosis","volume":"358","author":"Ivanova","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.heliyon.2024.e26658_bib8","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1007\/s00415-020-10025-z","article-title":"Cognitive impairment in benign multiple sclerosis: a multiparametric structural and functional MRI study","volume":"267","author":"Riccitelli","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.heliyon.2024.e26658_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102485","article-title":"Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration","volume":"46","author":"Ellenberger","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26658_bib10","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/jnnp-2018-318802","article-title":"How common is truly benign MS in a UK population?","volume":"90","author":"Tallantyre","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26658_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1259","article-title":"Impairment and restrictions in possibly benign multiple sclerosis","volume":"9","author":"Schaefer","year":"2019","journal-title":"Brain and behavior"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e26658_bib12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/jnnp-2018-319913","article-title":"Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study","volume":"90","author":"Crielaard","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.heliyon.2024.e26658_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2018.02.036","article-title":"Natural history of benign multiple sclerosis: clinical and HLA correlates in a Western Australian cohort","volume":"388","author":"Fabis-Pedrini","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.heliyon.2024.e26658_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ensci.2017.05.002","article-title":"Definition, prevalence and predictive factors of benign multiple sclerosis","volume":"7","author":"Reynders","year":"2017","journal-title":"eNeurologicalSci"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26658_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/1352458511419702","article-title":"Benign multiple sclerosis: a new definition of this entity is needed","volume":"18","author":"Correale","year":"2012","journal-title":"Multiple Sclerosis Journal"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e26658_bib16","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1177\/1352458511410343","article-title":"The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis","volume":"17","author":"Sayao","year":"2011","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26658_bib17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/jnnp.2010.210732","article-title":"How long can you keep working with benign multiple sclerosis?","volume":"82","author":"Glad","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e26658_bib18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/01.wnl.0000253185.03943.66","article-title":"Longitudinal follow-up of \u201cbenign\u201d multiple sclerosis at 20 years","volume":"68","author":"Sayao","year":"2007","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e26658_bib19","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1468-1331.2007.01810.x","article-title":"Predictive value of clinical characteristics for \u2018benign\u2019multiple sclerosis","volume":"14","author":"Ramsaransing","year":"2007","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e26658_bib20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-0404.2006.00637.x","article-title":"Benign course in multiple sclerosis: a review","volume":"113","author":"Ramsaransing","year":"2006","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.heliyon.2024.e26658_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1590\/0004-282x20170010","article-title":"Malignant multiple sclerosis: clinical and demographic prognostic factors","volume":"75","author":"Hampshire-Ara\u00fajo","year":"2017","journal-title":"Arq. Neuro. Psiquiatr."},{"issue":"23","key":"10.1016\/j.heliyon.2024.e26658_bib22","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1212\/WNL.0b013e31821e559d","article-title":"Demographic and clinical characteristics of malignant multiple sclerosis","volume":"76","author":"Gholipour","year":"2011","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e26658_bib23","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/jnnp-2013-304951","article-title":"Characterising aggressive multiple sclerosis","volume":"84","author":"Menon","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e26658_bib24","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1212\/WNL.58.9.1440-a","article-title":"Glatiramer acetate reduces the proportion of new MS lesions evolving into \u201cblack holes\u201d","volume":"58","author":"Richert","year":"2002","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.heliyon.2024.e26658_bib25","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: Report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26658_bib26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26658_bib27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1017\/cjn.2020.66","article-title":"Treatment optimization in multiple sclerosis: Canadian MS working group recommendations","volume":"47","author":"Freedman","year":"2020","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.heliyon.2024.e26658_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103857","article-title":"Effects of disease-modifying treatments discontinuation in patients with relapsing-remitting multiple sclerosis: a 5 year prospective cohort study","volume":"63","author":"Bawand","year":"2022","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26658_bib29","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/brain\/116.5.1077","article-title":"Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis","volume":"116","author":"Miller","year":"1993","journal-title":"Brain"},{"key":"10.1016\/j.heliyon.2024.e26658_bib30","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fneur.2017.00577","article-title":"Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments","volume":"8","author":"Weideman","year":"2017","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26658_bib31","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/brain\/awaa081","article-title":"Early clinical markers of aggressive multiple sclerosis","volume":"143","author":"Malpas","year":"2020","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26658_bib32","first-page":"1","article-title":"Epidemiologic data of multiple sclerosis in northern Greece during the last thirty years (1979-2008)","volume":"1","author":"Koutsouraki","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.heliyon.2024.e26658_bib33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0074-7742(07)79019-0","article-title":"Prognostic factors in multiple sclerosis","volume":"79","author":"Bergamaschi","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"issue":"1\u20132","key":"10.1016\/j.heliyon.2024.e26658_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jneuroim.2011.03.003","article-title":"Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms","volume":"234","author":"Greer","year":"2011","journal-title":"J. Neuroimmunol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e26658_bib35","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1212\/01.WNL.0000036907.37650.8E","article-title":"Course and prognosis in early-onset MS: comparison with adult-onset forms","volume":"59","author":"Simone","year":"2002","journal-title":"Neurology"},{"issue":"1\u20133","key":"10.1016\/j.heliyon.2024.e26658_bib36","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0165-0173(01)00137-0","article-title":"Interactions of estrogens and insulin-like growth factor-I in the brain: implications for neuroprotection","volume":"37","author":"Cardona-G\u00f3mez","year":"2001","journal-title":"Brain Res. Rev."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26658_bib37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/135245859900500306","article-title":"Prognostic factors for survival in multiple sclerosis","volume":"5","author":"Levi\u0107","year":"1999","journal-title":"Multiple Sclerosis Journal"},{"issue":"1\u20132","key":"10.1016\/j.heliyon.2024.e26658_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(01)00572-X","article-title":"Predicting secondary progression in relapsing\u2013remitting multiple sclerosis: a Bayesian analysis","volume":"189","author":"Bergamaschi","year":"2001","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26658_bib39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/brain\/103.2.281","article-title":"Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients","volume":"103","author":"Confavreux","year":"1980","journal-title":"Brain: a journal of neurology"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e26658_bib40","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archneur.1982.00510180015003","article-title":"Factors associated with a rapid course of multiple sclerosis","volume":"39","author":"Detels","year":"1982","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26658_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF00862981","article-title":"Prognostic criteria in an epidemiological group of patients with multiple sclerosis: an exploratory study","volume":"239","author":"Lauer","year":"1992","journal-title":"Journal of neurology"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26658_bib42","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/jnnp.58.3.300","article-title":"Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events","volume":"58","author":"Trojano","year":"1995","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26658_bib43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/brain\/116.1.117","article-title":"Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up","volume":"116","author":"Runmarker","year":"1993","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26658_bib44","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000110105","article-title":"Improvements to a simple Markov model of the natural history of multiple sclerosis","volume":"6","author":"Wolfson","year":"1987","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26658_bib45","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/brain\/114.2.1057","article-title":"The natural history of multiple sclerosis: a geographically based study: 4. Applications to planning and interpretation of clinical therapeutic trials","volume":"114","author":"Weinshenker","year":"1991","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26658_bib46","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1212\/WNL.51.3.765","article-title":"Survival and predictors of disability in Turkish MS patients","volume":"51","author":"Kantarci","year":"1998","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e26658_bib47","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/1352458509106511","article-title":"Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway","volume":"15","author":"Glad","year":"2009","journal-title":"Multiple Sclerosis Journal"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e26658_bib48","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1159\/000313457","article-title":"The onset of multiple sclerosis in Greece: a single-center study of 1,034 consecutive patients","volume":"63","author":"Koutsis","year":"2010","journal-title":"Eur. Neurol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e26658_bib49","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/jnnp.2010.208173","article-title":"The natural history of secondary progressive multiple sclerosis","volume":"81","author":"Koch","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26658_bib50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-510X(99)00143-4","article-title":"A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials","volume":"168","author":"Amato","year":"1999","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26658_bib51","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1600-0404.1981.tb00745.x","article-title":"Clinical studies on multiple sclerosis: I. presentation of an incidence material from Gothenburg","volume":"63","author":"Broman","year":"1981","journal-title":"Acta Neurol. Scand."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26658_bib52","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1600-0404.1992.tb04031.x","article-title":"Early prognostic factors for disability in multiple sclerosis, a European multicenter study","volume":"85","author":"Riise","year":"1992","journal-title":"Acta Neurol. Scand."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26658_bib53","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1600-0404.1984.tb00832.x","article-title":"Onset symptoms as predictors of mortality and disability in multiple sclerosis","volume":"70","author":"Visscher","year":"1984","journal-title":"Acta Neurol. Scand."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26658_bib54","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1600-0404.1970.tb05604.x","article-title":"Clinical factors associated with increased disability in multiple sclerosis","volume":"46","author":"Leibowitz","year":"1970","journal-title":"Acta Neurol. Scand."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26658_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-022-02609-1","article-title":"Epidemiology of familial multiple sclerosis in Iran: a national registry-based study","volume":"22","author":"Salehi","year":"2022","journal-title":"BMC Neurol."},{"issue":"1 Supp A","key":"10.1016\/j.heliyon.2024.e26658_bib56","first-page":"S24","article-title":"Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis","volume":"19","author":"Menzin","year":"2013","journal-title":"J. Manag. Care Pharm."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e26658_bib57","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1177\/1352458519877810","article-title":"The long-term outcomes of CIS patients in the Barcelona inception cohort: looking back to recognize aggressive MS","volume":"26","author":"Tintore","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e26658_bib58","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/brain\/awv105","article-title":"Defining high, medium and low impact prognostic factors for developing multiple sclerosis","volume":"138","author":"Tintore","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.heliyon.2024.e26658_bib59","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ensci.2017.05.002","article-title":"Definition, prevalence and predictive factors of benign multiple sclerosis","volume":"7","author":"Reynders","year":"2017","journal-title":"Eneurologicalsci"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26658_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2009.01221.x","article-title":"Black holes in multiple sclerosis: definition, evolution, and clinical correlations","volume":"122","author":"Sahraian","year":"2010","journal-title":"Acta Neurol. Scand."},{"issue":"1\u20132","key":"10.1016\/j.heliyon.2024.e26658_bib61","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jns.2013.04.021","article-title":"Integrating the tools for an individualized prognosis in multiple sclerosis","volume":"331","author":"Fernandez","year":"2013","journal-title":"J. Neurol. Sci."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024026896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024026896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:00:13Z","timestamp":1790712013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024026896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2405844024026896"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26658","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive factors and treatment challenges in malignant progression of relapsing-remitting multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e26658"}}